Clinical trials of a new drug therapy have shown unprecedented results in improving cognitive function for early-stage Alzheimer's patients, targeting the underlying mechanisms of the disease.
Clinical Trial Results
The Phase III trial involved 1,200 patients across 15 countries. Patients receiving the treatment experienced a 40% improvement in cognitive function compared to the control group.
Regulatory Pathway
The FDA has granted the treatment "Breakthrough Therapy" designation, which could see it available to patients within 18 months.